What began as a two week shutdown to “flatten the curve” has now extended to over two years of a total shift in society, with new health dangers emerging everyday. Alongside these hazards, breakthrough new technology has surfaced, and without delay it has been rapidly inserted into our everyday lives. Everything from 5G, to self-driving cars, to autonomous crime-fighting A.I. has appeared in major cities throughout the world. One of these invasive technologies, mRNA, is the latest craze throughout the medical community, and symbiotically their shareholders.
This revolutionary technology, mRNA is seen as a method of revenue to the pharmaceutical oligarchs and the iatrarchy. The digital cultural revolution has enacted a wave of propaganda, blurring the lines between what is essential for human health and what is an optional prophylactic. The Chinese Communist Party’s COVID-19 virus has now taken over 800,000 lives in America. While the initial surge of SARS-CoV-2 devastated the global populous, we as a species have survived, many seeing the emergence of Omicron variant as the natural weakening of the virus, calling conclusion to the end of an era many would like to forget.
Two years of our lives, and our liberties have been consumed by preventative health measures that have begun to feel like they may never end, many searching for a form of light at the end of tunnel. Could mRNA be that light? In the long-term, the data from Israel seems to suggest the contrary. Major pharmaceutical companies have pushed mRNA concoctions as a healthy, safe, solution to the pandemic. Now, Moderna has gained such confidence in this vaccine technology that they have fourteen vaccines in the works, as more effective alternatives. While the science shows the possibilities of this technology what risks can occur through routine injections of mRNA concoctions?
Moderna’s mRNA Vaccines
As of April 14, 2021 Moderna indicated the company fourteen different mRNA vaccine candidates had begun into clinical trials1. What started with the COVID-19 vaccine, now has expanded to include even mRNA flu shots, such as the mRNA-1010, which look to replace current standing influenza vaccines, as a more effective alternative.
A list of some of Moderna’s current mRNA vaccines under clinical trial
- mRNA-1273 – COVID-19 Vaccine2
- mRNA-1644 – HIV3
- mRNA-1574 – HIV4
- mRNA-1010 – Seasonal Flu Vaccine
- mRNA-1345 – Respiratory Syncytial Virus (RSV)
- mRNA-1189 – Epstein-Barr Virus Vaccine
- mRNA-1893 – Zika Virus Vaccine
- mRNA-4157 – Personalized Cancer Vaccine
- mRNA-1647 is a vaccine combining six mRNAs in a single vial
Just who funds Moderna’s mRNA vaccine manufacturing?
The main funders publicly displayed on the official website of Moderna are AstraZeneca, Merck, Vertex, BARDA, the Bill & Melinda Gates Foundation, DARPA, Karolinska, and Institut Pasteur.
Bill & Melinda Gates Foundation
Moderna describes entering a global health project with Bill Gates’ Foundation in 2016 with prospect to advance mRNA development. The Bill and Melinda Gates foundation donated tens of millions of dollars since that time.
“In January 2016, we [Moderna] entered a global health project framework agreement with the Bill & Melinda Gates Foundation to advance mRNA-based development projects for various infectious diseases.”
“The Bill & Melinda Gates Foundation has committed up to $20.0 million in grant funding to support our initial project related to the evaluation of antibody combinations in a preclinical setting as well as the conduct of a first-in-human Phase 1 clinical trial of a potential mRNA medicine to help prevent human immunodeficiency virus, or HIV, infections.”
“Follow-on projects which could bring total potential funding under the framework agreement up to $100.0 million (including the HIV antibody project) to support the development of additional mRNA-based projects for various infectious diseases can be proposed and approved until the sixth anniversary of the framework agreement, subject to the terms of the framework agreement, including our obligation to grant to the Bill &Melinda Gates Foundation certain non-exclusive licenses.”
“Moderna Therapeutics’ research has considerable potential for the development of an effective prevention intervention for HIV, and potentially other infectious diseases that disproportionately affect the world’s poorest people.”
— Trevor Mundel, president of Global Health at the Bill & Melinda Gates Foundation
Biomedical Advanced Research And Development Authority (BARDA)
BARDA is funded by the Department of Health and Human Services (DHSS), whose funding is provided by the federal government, who earns their living leeching from income taxes of the people. This means BARDA is funded entirely by the people, who are responsible for its ability to “award” Moderna $125 million dollars in 2016.
“In September 2016, we received an award of up to approximately $125 million from BARDA, a component of the Office of the Assistant Secretary for Preparedness and Response, or ASPR, within the U.S. Department of Health and Human Services, or HHS, to help fund our Zika vaccine program. Under the terms of the agreement with BARDA, an initial base award of approximately $8 million supported toxicology studies, a Phase 1 clinical trial, and associated manufacturing activities. Additionally, four contract options were awarded under the agreement with BARDA. Three out of four of these options have been exercised, bringing the total current award to approximately $117 million to support an additional Phase 1 study of an improved Zika vaccine candidate, Phase 2 and Phase 3 clinical studies, as well as large-scale manufacturing for the Zika vaccine.”
Defense Action Research Projects Agency (DARPA)
DARPA is funded by the Department of Defense’s (DOD) “science and technology” budget. This money comes from the federal government, who earns money from the income taxes of the people. This means the American populous, the hardworking taxpayers, are unknowingly shareholders which DARPA relies on for funding.
In 2013 DARPA had been resourced enough revenue to “award” Moderna approximate $25 million to research and develop mRNA vaccines.
“In October 2013, DARPA awarded Moderna up to approximately $25 million to research and develop potential mRNA medicines as a part of DARPA’s Autonomous Diagnostics to Enable Prevention and Therapeutics, or ADEPT, program, which is focused on assisting with the development of technologies to rapidly identify and respond to threats posed by natural and engineered diseases and toxins. This award followed an initial award from DARPA given in March 2013. The DARPA awards have been deployed primarily in support of our vaccine and antibody programs to protect against Chikungunya infection.”
“We have three alliances with AstraZeneca. Our first strategic alliance, established in 2013 to discover, develop, and commercialize potential mRNA medicines was for the treatment of cardiovascular and cardiometabolic diseases, as well as selected targets for cancer.”
“Together with Moderna, we are pushing the boundaries of science in the pioneering field of messenger RNA therapeutics. Where current drug discovery technologies can target only a fraction of the disease-relevant proteins in the human genome, we have the potential to create revolutionary new medicines to treat patients with serious cardiometabolic diseases and cancer.”
— Pascal Soriot, Chief Executive Officer of AstraZeneca5
“We have established a multi-faceted relationship with Merck that includes distinct strategic alliances directed to the research, development, and commercialization of mRNA medicines for the prevention and treatment of viral infections and cancer.”
“By combining Merck’s strength in vaccine and antiviral therapeutic development with Moderna’s mRNA Therapeutics technology, we are well positioned to develop differentiated candidates with the potential to provide meaningful benefit to patients. We look forward to working with the scientific and technical teams at Moderna.”
— Roger M. Perlmutter, M.D., Ph.D., President of Merck Research Laboratories
Just how much money has Moderna made off of the pandemic?
In the three months ending September 30th, Moderna’s expenses to bring their products to sale was $722 million. While an enormous cost, it was only fifteen-percent of their product sales.
In an SEC filing signed on November 4th, 2021 by Stéphane Bancel – Chief Executive Officer and Director, and David W. Meline – Chief Financial Officer of Moderna stated6,
“We began capitalizing our COVID-19 vaccine inventory costs in December 2020, in connection with an EUA from the FDA, and based upon our expectation that these costs would be recoverable through commercialization of our COVID-19 vaccine. Prior to the capitalization of our COVID-19 vaccine inventory costs, such costs were recorded as research and development expenses in the period incurred. We expensed $242 million of pre-launch inventory costs in 2020.”
“Our cost of sales was $722 million, or 15%, of our product sales, for the three months ended September 30, 2021, including third-party royalties of $168 million. Our cost of sales was $1.7 billion, or 16%, of our product sales, for the nine months ended September 30, 2021, including third-party royalties of $400 million. A portion of the inventory costs associated with our product sales for the nine months ended September 30, 2021 was expensed previously.”
“At the end of the first quarter of 2021, we had substantially utilized our zero-cost COVID-19 vaccine inventory. If inventory sold for the nine months ended September 30, 2021 was valued at cost, our cost of sales for the period would have been $1.9 billion, or 17%, of our product sales.”
“We expect that our cost of sales as a percentage of product sales will remain at a similar level for the remainder of 2021.”
“We expect our product sales to significantly increase in 2021 compared to 2020. As of September 30, 2021, we had signed supply agreements of approximately $25.1 billion for the future supply of our COVID-19 vaccine through 2023 and had deferred revenue of $8.3 billion associated with customer deposits received or billable under these agreements. Additional supply agreements have been agreed upon since September 30, 2021, and others are under discussion for 2021 and 2022 deliveries.”
“In addition, we expect to continue to receive funding from our contract with BARDA. As of September 30, 2021, the remaining available funding, net of revenue, earned under our agreement with BARDA for the development of our mRNA-1273 vaccine was $441 million. To the extent that existing or potential future products generate revenue, our revenue may vary due to many uncertainties in the independent development of our mRNA medicines and pursuant to our strategic alliances and other factors.”
Who is expecting a profit? In the most recent 2022 SEC filings, two massive entities reveal their commitments to the mRNA gold-rush. BlackRock Inc. and Ballie Gifford & Co.
Recent SEC filings give insight into the massive amount of investors currently expecting results, and progress from the company. With the COVID-19 pandemic hysteria winding down, many at this point are either fully vaccinated, or will never take the vaccine. Moderna must continue the momentum that ascended their pharmaceutical operation to become a household name. With the momentum of the massive interest in the company’s mRNA technology, Moderna has begun the rapid development of fourteen known mRNA vaccines, promising investors the same financial return seen with the coronavirus concoctions.
BlackRock Inc is a company valued at 10 trillion dollars. In comparison, the United States of America’s government is valued at negative 30 trillion dollars. Based on those statistics, which oligarchy holds more influential power?
Influence of the Chinese Communist Party – On September 8th, 2021 BlackRock Inc. announced a new investment fund in China, where Chinese investors, under the Chinese Communist Party, gave $1 billion in the first week7.
Controlling American Media – BlackRock Inc also alarmingly owns a large portion of media organizations, such as the New York Times, ABC, Fox, CNN, NBC, CBS, MSNBC, 60 Minutes, and Slate8.
Profiting off mRNA Vaccines – SEC filings from February 4th, 2022 show Spencer Fleming9, Managing Director at BlackRock in Wilmington, Delaware, as having reported 27,661,473 shares within Moderna10. At $153.00 per share, that is $4,232,205,369.00 USD.
At 4.2 Trillion dollars, BlackRock has over 40% of its company’s total value invested into Moderna’s mRNA.
With BlackRock valued at ten trillion dollars, News outlets will adhere to the narrative of what profits. In the case of BlackRock, that narrative is the rapid normalization and implementation of mRNA vaccines. The COVID-19 pandemic proved to be a predictably successful investment to accumulate revenue, with no chance of loss, for companies like BlackRock.
Baillie Gifford & Co
SEC filings from Janurary 26th, 2022 show Grant Meikle11, Baillie Gifford & Co as having reported 45,772,079 Moderna shares12. At $153.00 per share this is $7,003,128,087.00 USD.
Ballie Gifford expects Moderna’s shares to continue to increase, despite the pandemic hysteria beginning to wind down. This means other vaccines are on the way, and they will be as successful as Moderna’s first successful mRNA vaccine: the coronavirus concoction.
Ballie Gifford & Co released a company document13 entitled “Governance in China – Risk or Opportunity?”
- “China’s autocratic politics allow for a long-term vision that few in the Western world could countenance.”
- “Democratic countries struggling to work out who will be in power next month or next year, will struggle to rival President Xi Jinping’s ‘Vision for 2049”
- “Top-down development policies have driven phenomenal growth in recent decades, but this can be a double-edged sword. It is often seen to come at the expense of civil society, the rights of the private sector and of academic freedom.”
- “Modern corporate governance in China is closely linked to the rapid evolution of its capital markets.”
- “It is far too easy to make misleading generalisations about China.”
- “In China every individual and every entity is ultimately beholden to the Party and to the State.”
- “Loyalty is a cost of doing business.”
- “At Baillie Gifford, we are looking to provide patient capital to companies to whom thinking about corporate governance is not merely a compliance requirement, but a tool for enhancing long-term performance.”
- “The speed of change and the scale of the potential opportunities will lead to disruption that will cause winners and losers.”
“In 10 years since its inception, Moderna has transformed from a science research-stage company advancing programs in the field of messenger RNA (mRNA), to an enterprise with a diverse clinical portfolio of vaccines and therapeutics across six modalities, a broad intellectual property portfolio in areas including mRNA and lipid nanoparticle formulation, and an integrated manufacturing plant that allows for both clinical and commercial production at scale and at unprecedented speed.”
“Moderna maintains alliances with a broad range of domestic and overseas government and commercial collaborators, which has allowed for the pursuit of both groundbreaking science and rapid scaling of manufacturing. Most recently, Moderna’s capabilities have come together to allow the authorized use of one of the earliest and most-effective vaccines against the COVID-19 pandemic.”
While the funding of this innovative medical technology makes it possible to combat viruses and ensure the sustainability of our species, it also provides a genetic vulnerability that humans have never encountered before. The promise of profit through new mRNA technology has apparently surpassed the will to improve civilization and protect the future immunity of our species. To suggest the vaccines do not work, devours the investments and funding which define the existence of Moderna itself as a medical oligopoly. In order to keep up with the success of its first COVID-19 concoctions, Moderna must invest everything they have into prophylactic mRNA vaccines.
As the demand grows, the pressure continues to build on Moderna to rapidly produce successful mRNA vaccines which will be received by the majority of the population. Moderna has not taken on the commitment to make fringe vaccination which will only be sold to a minority of institutions, but products which can replace existing vaccines and other forms of health care, through artificial biological manipulation. If the vaccines are so safe and effective why are they equally mandated into the arms of every American regardless of their risk to SARS-CoV-2? Could humanity see further instances of mandated mRNA for the benefit of the population, future generations, the economy, and the medical dictatorship?
Are these medical innovations thoroughly tested, for the health and well-being of the future of humanity, or is it an attempt to make a fast-profit from newly created unregulated technology—like the accelerated emergence of 5G—before long-term health effects become apparent? Who is silently responsible for a great deal of the availability of the mRNA funding—and who controls the narrative of how that technology is implemented, mandated as a necessary measure? Is this technology being introduced with hopes of bringing new advancements to the medical field? Or is mRNA seen as a tool of modern profitability with forward thinking clinical trials, strategically coordinated to hustle money from the American taxpayer—demanding they be a participant in the mass medical experimentation?